Molecular and Cellular Analysis of Breast Cancer

Breast - Female Clinical Trial

Official title:

Molecular and Cellular Analysis of Breast Cancer

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT02243397
• Other study ID #: IRB-29691
• Secondary ID: BRS0040
• Status: Suspended
• Start date: September 2014
• Est. completion date: September 2024

Study information

• Verified date: February 2023
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to investigate the different types and subtypes of cells found in breast tumors. The investigators will do this using a variety of molecular analysis tools that may allow for improved tests. The different types of cells in breast cancer impacts the way individuals respond to various treatments.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 500
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Minutes and older

Eligibility

Inclusion Criteria:

1. Histologically proven diagnosis of breast cancer or a carcinoma of unknown primary consistent with the presentation of a primary breast malignancy.

2. 18 years of age or older.

3. Ability to understand and the willingness to sign a written informed consent do

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Breast - Female
• Breast - Male

Locations

Country	Name	City	State
United States	Stanford University Cancer Institute	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	levels of GM-CSF in plasma	We will be measuring levels of GM-CSF (Granulocyte-macrophayge colony stimulating factor) from the plasma of the patient before during and after the irradiation treatment to study if there is any increase in the GM-CSF production	10 years